189 related articles for article (PubMed ID: 19293153)
21. Profiles of ILY, VLY and Sm-hPAF interaction with human CD59.
Kawaguchi Y; Tabata A; Nagamune H; Ohkura K
Anticancer Res; 2013 Jul; 33(7):2901-4. PubMed ID: 23780977
[TBL] [Abstract][Full Text] [Related]
22. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
Sims PJ
Biochim Biophys Acta; 1983 Aug; 732(3):541-52. PubMed ID: 6871214
[TBL] [Abstract][Full Text] [Related]
23. High-resolution structures of bacterially expressed soluble human CD59.
Leath KJ; Johnson S; Roversi P; Hughes TR; Smith RA; Mackenzie L; Morgan BP; Lea SM
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Aug; 63(Pt 8):648-52. PubMed ID: 17671359
[TBL] [Abstract][Full Text] [Related]
24. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
[TBL] [Abstract][Full Text] [Related]
25. Binding of human complement C8 to C9: role of the N-terminal modules in the C8 alpha subunit.
Scibek JJ; Plumb ME; Sodetz JM
Biochemistry; 2002 Dec; 41(49):14546-51. PubMed ID: 12463754
[TBL] [Abstract][Full Text] [Related]
26. The cholesterol-dependent cytolysin signature motif: a critical element in the allosteric pathway that couples membrane binding to pore assembly.
Dowd KJ; Farrand AJ; Tweten RK
PLoS Pathog; 2012; 8(7):e1002787. PubMed ID: 22792065
[TBL] [Abstract][Full Text] [Related]
27. Rapid conditional targeted ablation model for hemolytic anemia in the rat.
Hanson MM; Liu F; Dai S; Kearns A; Qin X; Bryda EC
Physiol Genomics; 2016 Aug; 48(8):626-32. PubMed ID: 27368711
[TBL] [Abstract][Full Text] [Related]
28. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
Houle JJ; Hoffmann EM; Esser AF
Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
[TBL] [Abstract][Full Text] [Related]
29. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
30. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
Stewart JL; Monahan JB; Brickner A; Sodetz JM
Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
[TBL] [Abstract][Full Text] [Related]
31. Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.
Feng D; Dai S; Liu F; Ohtake Y; Zhou Z; Wang H; Zhang Y; Kearns A; Peng X; Zhu F; Hayat U; Li M; He Y; Xu M; Zhao C; Cheng M; Zhang L; Wang H; Yang X; Ju C; Bryda EC; Gordon J; Khalili K; Hu W; Li S; Qin X; Gao B
J Clin Invest; 2016 Jun; 126(6):2321-33. PubMed ID: 27159394
[TBL] [Abstract][Full Text] [Related]
32. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
33. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
34. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.
Huang Y; Fedarovich A; Tomlinson S; Davies C
Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):714-21. PubMed ID: 17505110
[TBL] [Abstract][Full Text] [Related]
36. Structure of C8alpha-MACPF reveals mechanism of membrane attack in complement immune defense.
Hadders MA; Beringer DX; Gros P
Science; 2007 Sep; 317(5844):1552-4. PubMed ID: 17872444
[TBL] [Abstract][Full Text] [Related]
37. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
Bhakdi S; Tranum-Jensen J
J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
[TBL] [Abstract][Full Text] [Related]
38. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
39. Characterization of tigurilysin, a novel human CD59-specific cholesterol-dependent cytolysin, reveals a role for host specificity in augmenting toxin activity.
Shahi I; Dongas SA; Ilmain JK; Torres VJ; Ratner AJ
Microbiology (Reading); 2023 Sep; 169(9):. PubMed ID: 37702594
[TBL] [Abstract][Full Text] [Related]
40. The human-specific action of intermedilysin, a homolog of streptolysin O, is dictated by domain 4 of the protein.
Nagamune H; Ohkura K; Sukeno A; Cowan G; Mitchell TJ; Ito W; Ohnishi O; Hattori K; Yamato M; Hirota K; Miyake Y; Maeda T; Kourai H
Microbiol Immunol; 2004; 48(9):677-92. PubMed ID: 15383705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
